Literature DB >> 17631544

Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT.

Hiroshi Matsuda1.   

Abstract

Structural MRI and functional imaging by SPECT as well as 18F-FDG PET are widely used in the diagnosis of Alzheimer's disease (AD). Metabolic and perfusion reductions in the parietotemporal association cortex are recognized as a diagnostic pattern for AD. Outstanding progress in the diagnostic accuracy of these modalities has been achieved with statistical analysis on a voxel-by-voxel basis after anatomic standardization of individual scans to a standardized brain volume template instead of visual inspection or a volume-of-interest technique. In a very early stage of AD, this statistical approach revealed losses of gray matter in the entorhinal and hippocampal areas and hypometabolism or hypoperfusion in the posterior cingulate cortex and precuneus. This statistical approach also offers a prediction of the conversion from mild cognitive impairment (MCI) to AD. The presence of hypometabolism or hypoperfusion in parietal association areas and entorhinal atrophy at the MCI stage have been reported to predict a rapid conversion to AD. A recent advance in voxel-based statistical analysis has markedly enhanced the value of brain perfusion SPECT in diagnosing early AD at the stage of MCI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631544     DOI: 10.2967/jnumed.106.037218

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  41 in total

1.  Role of Kinetic Modeling in Biomedical Imaging.

Authors:  Sung-Cheng Huang
Journal:  J Med Sci       Date:  2008

2.  Conformal invariants for multiply connected surfaces: Application to landmark curve-based brain morphometry analysis.

Authors:  Jie Shi; Wen Zhang; Miao Tang; Richard J Caselli; Yalin Wang
Journal:  Med Image Anal       Date:  2016-09-06       Impact factor: 8.545

3.  EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2.

Authors:  Ozlem L Kapucu; Flavio Nobili; Andrea Varrone; Jan Booij; Thierry Vander Borght; Kjell Någren; Jacques Darcourt; Klaus Tatsch; Koen J Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

4.  A review of neuroimaging biomarkers of Alzheimer's disease.

Authors:  Tinu Varghese; R Sheelakumari; Jija S James; Ps Mathuranath
Journal:  Neurol Asia       Date:  2013       Impact factor: 0.183

5.  Contrasting olfaction, vision, and audition as predictors of cognitive change and impairment in non-demented older adults.

Authors:  Stuart W S MacDonald; Connor J C Keller; Paul W H Brewster; Roger A Dixon
Journal:  Neuropsychology       Date:  2018-05       Impact factor: 3.295

Review 6.  Imaging approaches for dementia.

Authors:  A D Murray
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-01       Impact factor: 3.825

7.  Transient global amnesia: a study with Tc-99m ECD SPECT shortly after symptom onset and after recovery.

Authors:  Bom Sahn Kim; Sang Soo Cho; Joon Young Choi; Young Hwan Kim
Journal:  Diagn Interv Radiol       Date:  2016 Sep-Oct       Impact factor: 2.630

Review 8.  Current and future uses of neuroimaging for cognitively impaired patients.

Authors:  Gary W Small; Susan Y Bookheimer; Paul M Thompson; Greg M Cole; S-C Huang; Vladimir Kepe; Jorge R Barrio
Journal:  Lancet Neurol       Date:  2008-02       Impact factor: 44.182

9.  Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.

Authors:  Katsutoshi Furukawa; Nobuyuki Okamura; Manabu Tashiro; Masaaki Waragai; Shozo Furumoto; Ren Iwata; Kazuhiko Yanai; Yukitsuka Kudo; Hiroyuki Arai
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

10.  Cerebral blood flow is an earlier indicator of perfusion abnormalities than cerebral blood volume in Alzheimer's disease.

Authors:  María Lacalle-Aurioles; José M Mateos-Pérez; Juan A Guzmán-De-Villoria; Javier Olazarán; Isabel Cruz-Orduña; Yasser Alemán-Gómez; María-Elena Martino; Manuel Desco
Journal:  J Cereb Blood Flow Metab       Date:  2014-01-15       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.